EV / EBITDA společnosti Midatech Pharma Plc
Jaká je hodnota metriky EV / EBITDA společnosti Midatech Pharma Plc?
Hodnota metriky EV / EBITDA společnosti Midatech Pharma Plc je 0.40
Jaká je definice metriky EV / EBITDA?
EV/EBITDA je podniková hodnota dělená EBITDA (zisk před odečtením úroků, daní, odpisů a amortizací). Měří nákladnost akcie a používá se k porovnání společností mezi sebou častěji než P/E ratio. Měří cenu, jakou investor zaplatí za pohyb hotovosti ve společnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA společností v sektoru Health Care sektor na LSE ve srovnání se společností Midatech Pharma Plc
Čemu se věnuje společnost Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Firmy s metrikou ev / ebitda podobnou společnosti Midatech Pharma Plc
- Hodnota metriky EV / EBITDA společnosti Northern Bitcoin AG je 0.39
- Hodnota metriky EV / EBITDA společnosti Jilin Province Huinan Changlong Bio-pharmacy je 0.39
- Hodnota metriky EV / EBITDA společnosti Cassowary Capital je 0.39
- Hodnota metriky EV / EBITDA společnosti SciPlay je 0.40
- Hodnota metriky EV / EBITDA společnosti Mmtec je 0.40
- Hodnota metriky EV / EBITDA společnosti Meat-Tech 3D Ltd je 0.40
- Hodnota metriky EV / EBITDA společnosti Midatech Pharma Plc je 0.40
- Hodnota metriky EV / EBITDA společnosti Teras Resources je 0.40
- Hodnota metriky EV / EBITDA společnosti WestStar Industrial je 0.40
- Hodnota metriky EV / EBITDA společnosti Gulfport je 0.40
- Hodnota metriky EV / EBITDA společnosti SDX Plc je 0.40
- Hodnota metriky EV / EBITDA společnosti Harpoon Therapeutics je 0.41
- Hodnota metriky EV / EBITDA společnosti Litho Formas, S.A je 0.41